Myrmecia pilosula venom allergens (Myr p allergens)

Jack Jumper ant venom allergens are a group of potent proteins and peptides derived from the venom of the Australian ant Myrmecia pilosula (UniProt: P81461, P81462). The primary allergens, Myr p 1, Myr p 2, and Myr p 3, are responsible for severe IgE-mediated hypersensitivity reactions, which are a major cause of anaphylaxis in endemic regions of Australia (PubMed: 12781538). Biologically, these allergens, particularly the pilosulins, function as defensive toxins that disrupt cell membranes and induce histamine release from mast cells. In a therapeutic context, these allergens are the active components in venom immunotherapy (VIT), which is used to desensitize hypersensitive individuals. VIT works by shifting the immune response from a Th2-dominated allergic state to a Th1/Treg-mediated tolerant state (PubMed: 14585243). This process increases the production of blocking IgG4 antibodies and significantly reduces the risk of life-threatening systemic reactions upon subsequent stings. The high potency and prevalence of allergy to this venom make it a critical target for specialized immunotherapy programs. Clinical management involves both emergency treatment with epinephrine and long-term desensitization using standardized venom extracts. Monitoring of specific IgE and IgG4 levels is essential for assessing the efficacy and safety of the treatment.

Other names

Jack Jumper ant venomJJA venomMyrmecia pilosula allergensPilosulin

Allergen-specific immunotherapy (ASIT) involves the gradual administration of increasing doses of the venom allergens to induce immunological tolerance, characterized by a shift from a Th2 to a Th1 cytokine profile and the production of blocking IgG4 antibodies (PubMed: 14585243).